Pooled analysis indicated that the PASI 75 response rate for biologic therapy in erythrodermic psoriasis within 16 weeks was 69% (95% CI: 40%-73%), as shown in Figure 3A.Subgroup analyses were conducted for different targeted biologics used, with specific drugs and study numbers in each subgroup as follows: IL-17 inhibitors included secukinumab (n=6), ixekizumab (n=2), and brodalumab (n=1); IL-23 inhibitors included ustekinumab (n=1), risankizumab (n=1), and guselkumab (n=1); TNF-α inhibitors included etanercept (n=2), certolizumab (n=1), adalimumab (n=1), and infliximab (n=1). The gene discussed is IL37; the disease is psoriasis.